Key Highlights

  • KT-579 Phase 1 healthy volunteer trial demonstrated ≥90% median IRF5 degradation across multiple dose levels, with no serious adverse events.
  • The last patient completed their Week 16 visit in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial, with topline data expected by year-end 2026.
  • Kymera ended Q3 2026 with $1.6 billion in cash, providing runway into 2029.
  • The KT-579 LUMORA Phase 1b trial in lupus patients is planned to begin by early 2027.

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company developing oral small molecule degrader medicines for immunological diseases, reported third-quarter 2026 financial results alongside a significant pipeline milestone: positive Phase 1 healthy volunteer data for KT-579, its investigational IRF5 degrader. The data, which the company said met or exceeded study objectives, demonstrated deep, sustained degradation of the IRF5 target and meaningful suppression of Downstream inflammatory biomarkers. Kymera also reported that the final patient had completed their Week 16 visit in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial, with topline data anticipated by year-end 2026.

KT-579 Phase 1 Delivers Proof of Mechanism in Humans

In the multiple ascending dose portion of the KT-579 Phase 1 trial, the investigational compound demonstrated deep, sustained IRF5 degradation in blood, with median degradation of 90% or greater across multiple dose levels, with apparent saturation of degradation by the third dose level. Degradation was also observed in skin tissue, extending proof of mechanism beyond peripheral blood. Disease-relevant biomarkers showed marked suppression, including 88% inhibition of TNFα, 87% inhibition of IL-12/23p40, 94% inhibition of IL-1β, and 98% inhibition of IFNβ at Day 14. Broad downregulation of inflammatory cytokine, interferon, and B-cell associated gene transcripts was also documented.

From a safety standpoint, KT-579's profile was reported as comparable to placebo, with no serious or severe adverse events, no adverse events leading to discontinuation, and no clinically relevant changes in vital signs, laboratory tests, or electrocardiograms. The LUMORA Phase 1b trial testing KT-579 in approximately 30 adult patients with systemic lupus erythematosus is planned to begin by early 2027.

KT-621 Atopic Dermatitis Trial Reaches Key Readout Milestone

The KT-621 BROADEN2 Phase 2b trial in patients with moderate to severe atopic dermatitis completed its final patient visit at Week 16. Topline data from the trial are expected to be reported by the end of 2026, a readout that will inform the company's plans to initiate a Phase 3 atopic dermatitis trial, which is targeted for mid-2027 pending regulatory discussions. Enrollment is ongoing in the KT-621 BREADTH Phase 2b trial in patients with moderate to severe eosinophilic asthma, with topline data anticipated in late 2027.

KT-621, a once-daily oral degrader of STAT6 — the transcription Factor driving IL-4/IL-13 signaling and Type 2 inflammation — targets a patient population estimated at more than 140 million people globally across conditions including atopic dermatitis, asthma, and eosinophilic esophagitis, among others.

Financial Position and Partnered Programs

Kymera ended Q3 2026 with $1.6 billion in cash, providing a financial runway the company estimates extends into 2029. The cash balance supports continued Investment in both its proprietary pipeline and its Partnership activities. Under a collaboration with Sanofi, KT-485 (SAR447971), a second-generation IRAK4 degrader, is advancing through a Phase 1 clinical trial in healthy volunteers and hidradenitis suppurativa patients, with Sanofi leading development and commercial efforts. Gilead Sciences is also advancing a partnered degrader program.

The company described KT-579 as its seventh degrader to enter clinical testing, underscoring the productivity of its targeted protein degradation platform across a range of immunological targets and disease indications.

Kymera enters the final quarter of 2026 with two clinical programs in late-stage inflection points: KT-621 approaching a Phase 2b readout in atopic dermatitis and KT-579 validated in humans ahead of its Phase 1b lupus trial. The combination of these near-term data catalysts, a diversified partnership portfolio generating potential milestone payments, and a cash runway extending well into 2029 places the company in a position to transition from early-stage validation to late-stage execution across its flagship programs.